Released Feb 28, 2022, after the close
10-K filed Feb 28, 2022, 59 days after period end · 0000950170-22-002293
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.07M$17.07M derived+7.4% vs Q4 2020+20.0% vs Q3 2021
Net Income-$68.62M-$68.62M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$69,382,000N/M
Operating Cash Flowderived-$70,293,000N/M
Free Cash Flowderived-$88,662,000N/M
Margins · derived
Operating margin-406.5%−196.4 pt vs Q4 2020
Net margin-402.1%−68.0 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $17.07M | $15.90M | $2.80M | $1.66M |
| Net Income | -$68.62M | -$53.11M | -$28.30M | -$16.03M |
| EPS Diluted | — | — | -$0.37 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR